Table 11.

—[Sections 4.1.1-4.3] Thienopyridine Plus Aspirin vs Warfarin Plus Aspirin in the First Month Following PCI⁶⁸

Outcomes	Participants (Studies), Follow-up	Quality of the Evidence (GRADE)	Relative Effect (95% CI)	Anticipated Absolute Effects Over 30 d
				Risk With Warfarin and Aspirin	Risk Difference With Thienopyridine and Aspirin (95% CI)
Total mortality	2,436 (4 RCTs), 4-6 wk	Moderate due to imprecisiona	RR 0.73 (0.25-2.18)	7 per 1,000b	No significant difference; 2 fewer per 1,000 (from 5 fewer to 8 more)
MI nonfatal events	13,608 (1 RCT), 14.5 mo	Moderate due to risk of biasc	RR 0.50 (0.29-0.83)	39 per 1,000b	19 fewer per 1,000 (from 28 fewer to 7 fewer)
Stroke	This critical outcome was not reported in the meta-analysis
Major extracranial bleedd	2,436 (4 RCTs), 4-6 wk	Low due to inconsistency,e imprecision,a and risk of biasc	RR 0.38 (0.14-1.02)	64 per 1,000b	No significant difference; 40 fewer per 1,000 (from 55 fewer to 1 more)

See Table 1-3 legends for expansion of abbreviations.

^aWide CIs including benefit and harm (total mortality) or no benefit (major bleeding events).

^bControl group risk estimates come from the meta-analysis.

^cLack of blinding in RCTs.

^dBleeding definitions varied greatly across studies.

^eHeterogeneity was observed for major bleeding events (I = 72%).